The Discovery: A Missing element in Brain Health and What It May Mean for Alzheimer’s Disease

The brain under pressure of Alzheimer’s and a new budding hope for future therapeutic focus

Disclaimer: This blog discusses a review of recent ground-breaking research and is provided for general informational purposes only. Consult your physician if you are experiencing cognitive decline, dementia or alzheimer’s, or considering supplementation of any kind in relation to these conditions for appropriate individualized medical recommendations.

Alzheimer’s disease is often described as a condition of buildup, amyloid plaques accumulating, tau tangles spreading, memory slowly eroding. For decades, research has focused on what appears in excess.

But what if part of the story is about what quietly disappears first?

A landmark 2025 paper (1) published in Nature introduced a shift in perspective that may change how we think about brain aging and neurodegeneration. Researchers examining the brains of aging adults found that the earliest measurable biological change associated with Alzheimer’s disease was not amyloid or tau but a reduction in lithium within the brain itself.

Not psychiatric lithium. Not medication-level dosing. But endogenous lithium, the trace mineral that naturally exists in human brain tissue.

This finding reframes Alzheimer’s disease not only as a problem of toxic accumulation, but as a failure of physiological resilience.

Lithium: An Unexpected Player in Brain Aging

Lithium has long been associated with mental health treatment, but its role as a naturally occurring micronutrient is less commonly discussed. Lithium is present in soil, water, food, and in the human body at very small concentrations.

In the Nature study, scientists analyzed 27 different metals in post-mortem brain tissue from individuals with normal cognition, mild cognitive impairment (MCI), and Alzheimer’s disease.

Only one metal showed a consistent and significant decline early in the disease process.

That metal was lithium. (1)

• Lithium levels were significantly reduced in the prefrontal cortex of people with MCI

• Levels were further reduced in Alzheimer’s disease

• Blood lithium levels were unchanged, meaning the deficiency was localized to the brain

This suggests that lithium loss is not simply dietary, but tied to brain-specific pathology.

Why Does Brain Lithium Matter?

Lithium appears to act as a stabilizing influence across multiple brain systems. When present at physiological levels, it supports (1):

• Regulation of amyloid-β production

• Reduction of tau hyperphosphorylation

• Control of neuroinflammation

• Healthy microglial (immune cell) activity

• Preservation of synapses, axons, and myelin

In experimental models, reducing brain lithium by approximately 50% led to (1):

• Accelerated amyloid plaque formation

• Increased tau pathology

• Heightened inflammatory signaling

• Loss of synaptic connections

• Measurable declines in learning and memory

Importantly, these effects were observed not only in Alzheimer’s mouse models, but also in normal aging brains. This positions lithium not as a treatment target alone, but as part of the brain’s baseline protective architecture.

The Feedback Loop: How Amyloid Worsens Lithium Loss

One of the most striking findings from this research is how lithium is lost from the brain.

Amyloid plaques don’t just damage neurons. They bind lithium directly. (1)

As plaques form, lithium becomes sequestered inside them, reducing its availability in surrounding brain tissue. This creates a destructive loop:

1. Amyloid begins to accumulate

2. Lithium becomes trapped within plaques

3. Brain lithium availability drops

4. Protective signaling pathways weaken

5. Amyloid and tau pathology accelerate

This loop suggests that lithium loss may not only precede Alzheimer’s disease, but actively drive its progression.

GSK3β: The Molecular Switch

Lithium’s protective effects converge on a key enzyme called GSK3β, a regulator involved in (1-2):

• Tau phosphorylation

• Amyloid processing

• Inflammatory signaling

• Myelin integrity

• Synaptic maintenance

In Alzheimer’s disease, GSK3β activity is abnormally elevated. (1)

Lithium naturally suppresses this enzyme. (2) When lithium levels fall, GSK3β becomes overactive, contributing to many of the pathological features associated with cognitive decline.

When researchers restored lithium signaling, or directly inhibited GSK3β, many of the damaging effects were reversed.

This underscores an important theme: Alzheimer’s disease is a systems failure, not a single-target problem.

A Systems Lens on Prevention

At Near Me Therapy, we approach health through integration, not isolation.

The lithium discovery reinforces something we see clinically across disciplines: long before symptoms emerge, regulatory systems begin to strain. Inflammation rises. Repair mechanisms slow. Communication between systems weakens.

Brain health is deeply connected to:

• Movement and circulation

• Oral and systemic inflammation

• Nervous system regulation

• Metabolic and immune balance

Lithium appears to be one small but meaningful piece of that larger regulatory network.

Part one of this series is about awareness: understanding that cognitive decline may begin with subtle physiological changes long before diagnosis.

In Part Two, we’ll explore a critical follow-up question:

If lithium matters, does the type of lithium matter, what possible risks exist of supplementing, and how to engage with the research and your medical professionals for effective conversations about management or intervention involving lithium.

References

1.Aron, Liviu et al. “Lithium deficiency and the onset of Alzheimer's disease.” Nature vol. 645,8081 (2025): 712-721. doi:10.1038/s41586-025-09335-x

2. Pacholko, Anthony G, and Lane K Bekar. “Lithium orotate: A superior option for lithium therapy?.” Brain and behavior vol. 11,8 (2021): e2262. doi:10.1002/brb3.2262